Form 8-K GENEREX BIOTECHNOLOGY For: Jan 06

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549 FORM 8-K

CURRENT
REPORT

Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date
of Report (Date of earliest event reported): January 6, 2021

GENEREX
BIOTECHNOLOGY CORPORATION

(Exact
of registrant as specified in its charter)

10102
USA Today Way, Miramar, Florida 33025

(Address
of principal executive offices) (Zip Code)

(416)
364-2551

(Registrant’s
telephone number, including area code)

(Former name or former address, if changed since last report.)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ☐

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. ☐

Securities
registered pursuant to Section 12(b) of the Act:

Item
1.01 Entry into a Material Definitive Agreement. 

On
January 6, 2021, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively
“Generex”) agreed to accept a One Hundred Thousand Dollar USD ($100,000.00) “Performance Guarantee Fee”
payment to extend, for a second time, the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint
Entity” (the “Performance Guarantee Fee Agreement”) as set forth under the Ii-Key Innovative Vaccine Development
Agreement signed November 13, 2020, as amended by the extension terms signed December 15, 2020 (collectively the “Agreement”),
with Beijing Youfeng International Consulting Co., Ltd (“BYIC”), National Institute for Viral Disease Control and
Prevention,…